Format

Send to

Choose Destination
Ann Oncol. 1999 Jan;10(1):115-7.

Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.

Author information

1
Med. Klinik III, Johann Wolfgang Goethe-Universit├Ątsklinik, Frankfurt/Main, Germany. rummel@em.uni-frankfurt.de

Abstract

PURPOSE:

Cladribine (2-chlorodeoxyadenosine, 2-CdA) has been reported to be effective in the treatment of low-grade lymphomas. The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine.

PATIENTS AND METHODS:

A total of 47 courses, or an average of four courses per patient, were administered to 12 patients (seven untreated, five relapsed) with 5 mg/m2 cladribine given as an intermittent two-hour infusion over five consecutive days for a maximum of six cycles every four weeks.

RESULTS:

Cladribine showed activity in patients with mantle-cell lymphomas, achieving a response rate of 58% (95% confidence interval (95% CI): 28%-85%). Myelosuppression was the major toxicity with 17% of grade 3 and 4 neutropenia. Thrombocytopenia was rare with only 2% of grade 3 and 4.

CONCLUSION:

These results demonstrate single-agent activity of cladribine in mantle-cell lymphomas using the intermittent two-hour infusion dosage regimen. To further improve treatment results, cladribine should be combined with other agents active in mantle-cell lymphomas.

PMID:
10076731
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center